GPP
VYNE icon

Great Point Partners’s VYNE Therapeutics VYNE Stock Holding History

Great Point Partners’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-22,945
Closed -$4.43M – 41
2020
Q1 		$4.43M Hold
22,945
– – 0.46% 31
2019
Q4 		$7.67M Hold
22,945
– – 0.67% 27
2019
Q3 		$7.4M Sell
22,945
-1,137
-5% -$367K 0.68% 32
2019
Q2 		$10.4M Sell
24,082
-4,488
-16% -$2.22M 1.15% 21
2019
Q1 		$16.1M Sell
28,570
-2,047
-7% -$982K 1.6% 22
2018
Q4 		$9.08M Buy
30,617
+12,500
+69% +$5.6M 1.15% 29
2018
Q3 		$12.8M Buy
+18,117
New +$11.2M 2% 19
2018
Q2 		– Sell
-722
Closed -$1.95M – 45
2018
Q1 		$1.95M Buy
+722
New +$1.76M 0.29% 31

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Great Point Partners's VYNE Position: Q2 2020 in Review

Great Point Partners sold out of VYNE Therapeutics (VYNE) in Q2 2020, closing a stake of 22,945 shares — an estimated $4.43M sold.

Great Point Partners first reported a position in VYNE in Q1 2018 and held it in 8 quarters. The position peaked at $16.1M in Q1 2019. 106 funds tracked by Wall St. Rank hold VYNE as of Q2 2020.

  • Great Point Partners reported no remaining VYNE Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Great Point Partners sold 22,945 VYNE Therapeutics shares in Q2 2020, an estimated $4.43M.
  • Great Point Partners first reported a position in VYNE Therapeutics in Q1 2018 and held it in 8 quarters.
  • Great Point Partners's VYNE Therapeutics position peaked at $16.1M in Q1 2019.
  • 106 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2020.

Based on Great Point Partners's 13F filing for Q2 2020, filed 14 Aug 2020.